Interferon alpha-2a recombinant

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Healthy SubjectsPsoriasis

Phase 1

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

CompletedNCT02534636

Bristol-Myers SquibbHealthy Subjects

Start: 2015-10-31End: 2016-11-30Updated: 2016-12-28

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

CompletedNCT02763969

Bristol-Myers SquibbPsoriasis

Start: 2016-05-18End: 2016-12-15Updated: 2017-08-03

Related Papers

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

Dermatology and Therapy2023-11-195 citations

<scp>First‐in‐human</scp> study of deucravacitinib: A selective, potent, allosteric <scp>small‐molecule</scp> inhibitor of tyrosine kinase 2

Clinical and Translational Science2022-11-0352 citations